Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer

Abstract Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the standard first-line treatment for metastatic estrogen receptor–positive, HER2-negative breast cancer, yet acquired resistance remains a major challenge. Reliable biomarkers for prognostic stratification are therefore needed. We retros...

Descripción completa

Detalles Bibliográficos

Autores principales:	Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea d’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Barbara Bobek-Billewicz, Daria Handkiewicz-Junak, Michał Jarząb
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2026-05-01
Colección:	npj Breast Cancer
Acceso en línea:	https://doi.org/10.1038/s41523-026-00962-9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!